We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Faces Another Antitrust Suit Over Relafen Patent

Law360 (October 1, 2004, 12:00 AM EDT) -- GlaxoSmithKline, which already has agreed to pay over $250 million to settle charges it broke antitrust law by trying to block generic competition for the arthritis drug Relafen, is facing accusations...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.